Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Strategies for Optimal HIV Treatment and Prevention: Considering a Switch to Long-Acting ART

In this case example, learn data and recommendations for considering a switch to long-acting CAB plus RPV, including current indications and contraindications, data for “direct to inject” without an oral lead-in, and considerations for dosing every 8 weeks vs every 4 weeks.
Darcy Wooten, MD
Released: July 22, 2022

Information on this Educational Activity

Faculty

Darcy Wooten, MD

Associate Professor of Medicine
Division of Infectious Diseases and Global Public Health
Department of Medicine
University of California, San Diego
San Diego, California

Darcy Wooten, MD, has no relevant financial relationships to disclose.

Staff

Jessica Adams, PharmD, BCPS, AAHIVP

Scientific Director

Jessica Adams, PharmD, BCPS, has no relevant financial relationships to disclose.
Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant financial relationships to disclose.
Zachary Schwartz, MSc

Scientific Director

Petra Cravens, PhD, has no relevant financial relationships to disclose.
Jennifer Blanchette, PhD

Senior Scientific Director

Jennifer Blanchette, PhD, has no relevant financial relationships to disclose.

Program Medium

This program has been made available online.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings